Data / Form D filings / EUPRAXIA PHARMACEUTICALS INC.
EUPRAXIA PHARMACEUTICALS INC.: Form D filings
EUPRAXIA PHARMACEUTICALS INC., a biotechnology company in Victoria, British Columbia, Canada, filed 8 Form D notices with the SEC between 2013 and 2024. The latest, on November 8, 2024, reports $1.9 million sold of a $1.9 million offering to 6 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 201-2067 CADBORO BAY RD., Victoria, British Columbia, Canada, V8R 5
- Phone
- (250) 590-3968
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- British Columbia, Canada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1581178
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 8, 2024 | New notice | $1,894,413 | $1,894,413 | 6 | Oct 31, 2024 | sec.gov | |
| Aug 22, 2023 | New notice | $128,394 | $128,394 | 3 | Aug 18, 2023 | sec.gov | |
| Apr 18, 2016 | New notice | $37,951 | $37,951 | 1 | Apr 5, 2016 | sec.gov | |
| Sep 16, 2013 | New notice | $24,277 | $24,277 | 1 | Jul 24, 2013 | sec.gov | |
| Jul 11, 2013 | New notice | $23,782 | $23,782 | 1 | Jun 30, 2013 | sec.gov | |
| Jul 11, 2013 | New notice | $645,089 | $376,848 | $268,241 | 14 | Dec 21, 2012 | sec.gov |
| Jul 11, 2013 | New notice | $12,665 | $5,066 | $7,599 | 1 | Oct 3, 2012 | sec.gov |
| Jul 11, 2013 | New notice | $10,139 | $10,139 | 1 | Aug 31, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Simon Pimstone | Director | |
| Mark Kowalski | Executive Officer | |
| Richard Glickman | Director | |
| Bruce Cousins | Executive Officer | |
| James Helliwell | Executive Officer, Director | |
| Rahul Sarugaser | Executive Officer | |
| Paul Brennan | Executive Officer | |
| Paul Geyer | Director | |
| Joseph Freedman | Director | |
| Amanda Malone | Executive Officer | |
| John Montalbano | Director | |
| Michael Wilmink | Director |
Every Form D from the week of Nov 4, 2024 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what EUPRAXIA PHARMACEUTICALS INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.